J.P. Brito, S. Payne, N. Singh Ospina, R. Rodriguez-Gutierrez, S. Maraka, L.R. Sangaralingham, N.M. Iñiguez-Ariza, V.M. Montori, M.N. Stan, Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid 30(3), 357–364 (2020)

Article  CAS  PubMed  Google Scholar 

C.M. van Kinschot, V.R. Soekhai, E.W. de Bekker-Grob, W.E. Visser, R.P. Peeters, T.M. van Ginhoven, C. van Noord, Preferences of patients and clinicians for treatment of Graves’ disease: a discrete choice experiment. Eur. J. Endocrinol. 184(6), 803–812 (2021)

Article  PubMed  Google Scholar 

F. Azizi, R. Malboosbaf, Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27(10), 1223–1231 (2017)

Article  PubMed  Google Scholar 

F. Azizi, V. Yousefi, A. Bahrainian, F. Sheikholeslami, M. Tohidi, Y. Mehrabi, Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch. Iran. Med. 15(8), 0–0 (2012)

Google Scholar 

O.M. El Kawkgi, D.S. Ross, M.N. Stan, Comparison of long‐term antithyroid drugs versus radioactive iodine or surgery for Graves’ disease: a review of the literature. Clin. Endocrinol. 95(1), 3–12 (2021)

Article  Google Scholar 

D. Villagelin, J.H. Romaldini, R.B. Santos, A.B. Milkos, L.S. Ward, Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25(12), 1282–1290 (2015)

Article  CAS  PubMed  Google Scholar 

F. Azizi, A. Amouzegar, M. Tohidi, M. Hedayati, D. Khalili, L. Cheraghi, Y. Mehrabi, M. Takyar, Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid 29(9), 1192–1200 (2019)

Article  CAS  PubMed  Google Scholar 

G.J. Kahaly, L. Bartalena, L. Hegedüs, L. Leenhardt, K. Poppe, S.H. Pearce, 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur. Thyroid J. 7(4), 167–186 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10), 1343–1421 (2016)

Article  PubMed  Google Scholar 

F. Azizi, H. Abdi, A. Amouzegar, Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr. Disord. 21(1), 1–7 (2021)

Article  Google Scholar 

T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58(2), 95–100 (2011)

Article  CAS  PubMed  Google Scholar 

D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J. Herry, H. Allannic, Antithyroid drugs and Graves’ disease—prospective randomized assessment of long‐term treatment. Clin. Endocrinol. 50(1), 127–132 (1999)

Article  CAS  Google Scholar 

E. Mazza, M. Carlini, D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba, S. Beninati, M. Messina, Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol Investig. 31(10), 866–872 (2008)

Article  CAS  Google Scholar 

K. Shizume, M. Irie, S. Nagataki, F. Matsuzaki, Y. Shishiba, H. Suematsu, T. Tsushima, Long-term result of antithyroid drug therapy for Grave’s disease follow up after more than 5 years. Endocrinol Japonica 17(5), 327–332 (1970)

Article  CAS  Google Scholar 

K. Okamura, S. Bandai, M. Fujikawa, K. Sato, H. Ikenoue, T. Kitazono, Long-term antithyroid drug treatment: Trends in serum TSH and TSH receptor antibody changes in patients with Graves' disease. Int. J. Endocrinol. Metab. 18(Suppl), e101139:1–8 (2020)

Article  Google Scholar 

C. Perez, N.S. Scrimshaw, J. Munoz, Technique of endemic goitre surveys. Monogr. Ser. World Health Organ 44, 369–383 (1960)

CAS  PubMed  Google Scholar 

D. Hermsen, M. Broecker-Preuss, M. Casati, J.C. Mas, A. Eckstein, D. Gassner, J. van Helden, K. Inomata, J. Jarausch, J. Kratzsch, Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin. Chim. Acta 401(1-2), 84–89 (2009)

Article  CAS  PubMed  Google Scholar 

A. Amouzegar, H. Delshad, L. Mehran, M. Tohidi, F. Khafaji, F. Azizi, Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. J. Endocrinol Investig. 36(11), 950–954 (2013)

CAS  Google Scholar 

E. Piantanida, A. Lai, L. Sassi, D. Gallo, E. Spreafico, M. Tanda, L. Bartalena, Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm. Metab. Res. 47(10), 767–772 (2015)

Article  CAS  PubMed  Google Scholar 

D.G. Kleinbaum, Epidemiologic methods: the “art” in the state of the art. J. Clin. Epidemiol. 55(12), 1196–1200 (2002)

Article  PubMed  Google Scholar 

Steyerberg E.W.: Overfitting and optimism in prediction models. In: Clinical prediction models. Springer; 2019: 95-112.

K.P. Burnham, D.R. Anderson, Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 33(2), 261–304 (2004)

Article  Google Scholar 

U. Feldt-Rasmussen, H. Schleusener, P. Carayon, Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J. Clin. Endocrinol. Metab. 78(1), 98–102 (1994)

CAS  PubMed  Google Scholar 

O. Törring, L. Tallstedt, G. Wallin, G. Lundell, J.-G. Ljunggren, A. Taube, M. Sääf, B. Hamberger, Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid Study Group. J. Clin. Endocrinol. Metab. 81(8), 2986–2993 (1996)

PubMed  Google Scholar 

P.-W. Wang, Prediction of relapse after antithyroid drugs withdrawal: A narrative review. Int. J. Endocrinol. Metab. 18(Suppl), e102346:1–8 (2020)

Article  Google Scholar 

A.K. Eckstein, H. Lax, C. Lösch, D. Glowacka, M. Plicht, K. Mann, J. Esser, N.G. Morgenthaler, Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. 67(4), 607–612 (2007)

Article  Google Scholar 

N.N.Z. Tun, G. Beckett, N.N. Zammitt, M.W. Strachan, J.R. Seckl, F.W. Gibb, Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid 26(8), 1004–1009 (2016)

Article  CAS  PubMed  Google Scholar 

B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid 15(9), 1047–1054 (2005)

Article  CAS  PubMed  Google Scholar 

C. Carella, G. Mazziotti, F. Sorvillo, M. Piscopo, M. Cioffi, P. Pilla, R. Nersita, S. Iorio, G. Amato, L. Braverman, Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16(3), 295–302 (2006)

Article  CAS  PubMed  Google Scholar 

F. Azizi, Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid 30(10), 1451–1457 (2020)

Article  CAS  PubMed  Google Scholar 

F. Azizi, H. Abdi, L. Mehran, A. Amouzegar, Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. J. Endocrinol. Investig. 45(6), 1139–1150 (2022)

Article  CAS  Google Scholar 

D.S. Cooper, Long-term antithyroid drug therapy. Curr. Opin. Endocrinol., Diabetes Obes. 28(5), 510–516 (2021)

Article  CAS  PubMed  Google Scholar 

R. Malboosbaf, F. Azizi, Long-term treatment with antithyroid drugs: Efficacy and safety. Int. J. Endocrinol. Metab. 18(Suppl), e101487:1–10 (2020)

Article  Google Scholar 

T. Struja, H. Fehlberg, A. Kutz, L. Guebelin, C. Degen, B. Mueller, P. Schuetz, Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur. J. Endocrinol. 176(1), 87–97 (2017)

Article  CAS  PubMed  Google Scholar 

X.G. Vos, E. Endert, A. Zwinderman, J.G. Tijssen, W.M. Wiersinga, Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 101(4), 1381–1389 (2016)

Article  CAS  PubMed  Google Scholar 

M. Preus, M. Frecker, V. Stenszky, C. BALAŠS, N. Farid, A prognostic score for Graves’ disease. Clin. Endocrinol. 23(6), 653–661 (1985)

Article  CAS  Google Scholar 

A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn, Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 85(3), 1038–1042 (2000)

CAS  PubMed  Google Scholar 

P. Anagnostis, F. Adamidou, S.A. Polyzos, S. Katergari, E. Karathanasi, C. Zouli, A. Panagiotou, M. Kita, Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 44(2), 448–453 (2013)

Article  CAS  PubMed  Google Scholar 

E. Masiello, G. Veronesi, D. Gallo, P. Premoli, E. Bianconi, S. Rosetti, C. Cusini, J. Sabatino, S. Ippolito, E. Piantanida, Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J. Endocrinol Investig. 41(12), 1425–1432 (2018)

Article  CAS  Google Scholar